$2.000
-0.058 (-2.91%)At close
RGNT News
RGNT Events
Regentis Biomaterials Receives Approval to Manufacture GelrinC
Regentis Biomaterials announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process. The approval comes as Regentis prepares for the commercial launch of GelrinC in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by approximately 400%, delivering five times more product from the same manufacturing volume while improving manufacturing efficiency and scalability.
Selling Stockholders Plan to Sell 3.81M Ordinary Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.81M ordinary shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Core AI Holdings Appoints Arie Goor as CFO
Core AI Holdings (CHAI) announced the appointment of Arie Goor as its CFO, effective July 1. Goor joins Core AI Holdings with more than 15 years of executive financial leadership experience spanning corporate finance, capital markets, strategic transactions, and financial management across the biotechnology, medical device, and technology sectors. Prior to joining Core AI Holdings, Goor served as CFO of Regentis Biomaterials (RGNT).
Regentis Biomaterials Completes $6.5 Million Private Placement
Regentis Biomaterials "announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or pre-funded warrants in lieu thereof) together with warrants , at a purchase price of $3.50 per ordinary share and accompanying ordinary warrant (or $3.4999 per pre-funded warrant and accompanying ordinary warrant), in a private placement, for expected aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and estimated offering expenses payable by us. The Company intends to use the net proceeds from the private placement to support continued execution of its pivotal clinical trial for GelrinC and to advance preparation of the pre-market approval submission to the Food and Drug Administration; to advance its Gelrin technology platform as well as product optimization; to support operational readiness, including manufacturing scale-up, regulatory affairs, and intellectual property protection; to support European market entry activities, including Medical Device Regulation compliance, marketing activities and related scale-up efforts and for working capital and general corporate purposes. ThinkEquity is acting as the exclusive placement agent in connection with the private placement."
Regentis Biomaterials Ltd Trading Halted Due to Volatility Trading Pause
Regentis Biomaterials Ltd trading halted, volatility trading pause
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.